Cytogenetic studies have an important role in the diagnosis and prognosis of hematological malignancies, but the conventional karyotype analysis in acute lymphoblastic leukemia (ALL) is often hampered by suboptimal chromosome morphology, low lymphoblast mitotic activity, and inability to detect subtle (o5-10 Mb) abnormalities. With the combination of karyotype analysis and fluorescence in situ hybridization (FISH), cytogenetic studies of chromosome aberrations have become a major and reliable marker for risk assignment and risk-directed treatment of pediatric B-cell ALL. 1 In contrast to B-cell ALL, T-cell ALL (T-ALL) is associated with few unique cytogenetic features on which to base risk-group stratification. Recently, a few genome-wide microarray studies have revealed submicroscopic chromosome aberrations in T-ALL. [2] [3] [4] To identify submicroscopic chromosome aberrations in pediatric patients with a well-defined diagnosis of T-ALL and to determine the feasibility of incorporating a newly developed 133K-targeted oligonucleotide-based microarray platform into routine cytogenetic diagnosis, we used this comprehensive system to analyze DNA from cryopreserved diagnostic leukemia samples and compared microarray findings to their reported bone marrow karyotypes. Multiple submicroscopic abnormalities in each of these samples have been revealed with many recurrent abnormalities.
This study included 22 leukemia bone marrow samples from the Children's Oncology Group (COG) Cell Bank. These specimens were collected, with informed consent for future research use and institutional review board approval, from children with T-ALL who were treated on COG ALL clinical trials. Mononuclear cells were purified by Ficoll-Hypaque centrifugation prior to cryopreservation. All specimens consisted of 490% lymphoblasts. Samples were selected based on the presence of an identified deletion or rearrangement involving chromosome 6q (originally designed to validate the microarray analysis). The T-ALL diagnosis and the diagnostic karyotypes received COG central review. Oligonucleotide-based microarray analysis was performed using a custom-designed 133K-feature whole-genome microarray (Signature OncoChip, manufactured by RocheNimbleGen, Madison, WI, USA). The custom-designed array targeted 41800 genes and genomic intervals associated with cancer at a probe spacing ranging from B1 probe per 0.2-7.0 kb. In addition, the genomic backbone of the array had an average spacing of B1 probe per 35 kb. Array comparative genomic hybridization analysis was performed as described previously. 5 Karyotypes of the 22 patient samples included the following: deletion in 6q (n ¼ 11), deletion in 6q with additional abnormalities (n ¼ 7), and apparently normal (n ¼ 4) ( Table 1) . Microarray analysis detected the abnormalities identified by karyotyping, and refined precise deletion and/or rearrangement boundaries (Figure 1a ). More significantly, this high-resolution microarray analysis led to the identification of additional submicroscopic deletions and rearrangements in each of the 22 patients (Table 1) . 
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Although our analysis included a limited sample size of 22, the frequencies of various types of submicroscopic abnormalities identified in these patients are in agreement with previously reported findings. The most common submicroscopic deletion, in 18 of the 22 patients, was in 9p21.3, which harbors tumor suppressor genes CDKN2A/CDKN2B. These deletions were either monoallelic or biallelic, and ranged from 24 kb to 6.8 Mb (Table 1 and Figure 1b) . Interestingly, six cases had a distal breakpoint defined by one of two adjacent oligonucleotides within 48 kb of the 3 0 end of CDKN2A. Although sequencing of these breakpoints was not performed, the results would be consistent with a common mechanism for the formation of deletions in this disorder, as has been previously proposed. 6 Three of the smaller deletions involved CDKN2A, but were distal to and did not include CDKN2B. This result is consistent with previous reports that found CDKN2A deleted in 65% of T-ALL patients, whereas CDKN2B was deleted in only 23% of patients. 7 A deletion of approximately 80 kb in 1p33 leading to a STIL-TAL1 fusion was found in 9 of the 22 patients who shared a precise breakpoint at the promoter of STIL (previously termed SIL) (Figure 1c ). This submicroscopic deletion places TAL1 under control of the STIL promoter to induce overexpression of TAL1. 8 PTEN deletions in 10q23.31, ranging from 15 kb to 1 Mb, were detected in 6 patients (Figure 1d) . A recent study of the PTEN-PI3K-AKT pathway in T-ALL linked the deletions that disrupt the phosphatase domain of PTEN to a more adverse therapeutic consequence. 4 Additional submicroscopic aberrations were observed in single cases in this group. Case 19 had an apparent normal karyotype. A cryptic deletion was detected in 9q34, resulting in a SET-NUP214 fusion (Figure 1e ). This fusion has been reported in a number of patients with T-ALL. The fusion product is believed to contribute to leukemogenesis through a HOXA activation mechanism. 9 In case 20, which also had an apparent normal karyotype, a 181-kb deletion in 4q25 involving LEF1 was identified. Inactivation of LEF1 is an important step in the pathogenesis of T-ALL.
Another deletion of protein tyrosine phosphatase nonreceptor type 2 (PTPN2) has been described recently in T-ALL. 10 PTPN2 is a negative regulator of tyrosine kinases and the deletions involving this gene are typically seen in patients with aberrations indicative of tyrosine kinase overexpression. A 94-kb PTPN2 deletion was seen in case 21, again with a normal karyotype. Importantly, this case also showed a 364-kb duplication between the ABL1 and NUP214 genes. Although not confirmed, this duplication is likely indicative of a genomic rearrangement involving these genes, as the presence of an ABL1-NUP214 fusion was previously identified in patients with PTPN2 deletions. In addition, a loss of 5q35.1-q35.5 and gain of 14q32.2-q32.33 was detected in this case, most likely representing an unbalanced t(5;14) translocation activating the TLX3. FISH analysis using a TLX3-rearrangement probe confirmed the loss of telomeric end of the TLX3 gene. Another TLX3 rearrangement was noted in case 13 where again the FISH probe confirmed loss of the telomeric end of the TLX3 gene. TLX3 rearrangements frequently coexist with other genetic defects in pediatric T-ALL. 2 A novel finding from our analysis was the identification of a recurrent gain of 13q31.2-q31.3 in three patients (cases 12, 16 and 18; karyotype identified the gain as additional material of unknown origin in two cases), with a minimal shared region of B5 Mb (Figure 1f) . Notably, microRNA (miRNA) cluster miR-17-92, containing six individual miRNAs with oncogenic functions, resides in this region. Overexpression of these miRNAs has been documented in various types of solid tumors including B-cell lymphoma. 11 This observation led us to investigate the expression of these miRNAs in T-ALL. We analyzed expression levels of miR-17 and miR-20a, which influence cell-cycle progression by targeting cyclin-dependent kinase inhibitor CDKN1A (p21), 11 as well as miR-19, which promotes leukemogenesis in Notch1-induced T-ALL in vivo.
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Total RNA was extracted from cells using a mirVana PARIS Kit (Ambion, Austin, TX, USA). cDNA was generated from 10 ng of total RNA using miRNA-specific stemloop RT primers. Quantitative RT-PCR assays were performed following manufacturer's instructions. PCR reactions were run in an IQ5 (BioRad, Hercules, CA, USA). miR-17 (02308, Applied Biosystems, Foster City, CA, USA), miR-20a (000580, Applied Biosystems) and miR-19b (000396, Applied Biosystems) expressions were normalized to RNU6B (001093; Applied Biosystems). In comparison with CD2 þ T cells from a normal control, the three miRNAs displayed increased expression in six T-ALL cases, with three cases showing and three cases not showing a gain of the 13q31 (Figure 2 ). Although the increased expression does not appear to directly associate with the genomic gain of 13q31, overexpression of this miRNA cluster may represent a previously unappreciated event contributing to the development of T-ALL.
In summary, we have demonstrated in this study that (1) submicroscopic genomic imbalances are common in pediatric T-ALL and likely represent cooperative events in leukemogenesis, and (2) the microarray analyses allow for a comprehensive assessment of chromosomal aberrations in T-ALL. Although the detection of balanced rearrangements remains as a challenge, microarray analysis can precisely define the breakpoints in known karyotype abnormalities and reveal additional genomic imbalances. Novel findings, such as the gain of 13q31, may provide additional prognostic value and novel treatment targets. Taken together, microarray analysis improves the power of cytogenetic diagnosis of T-ALL and should facilitate patient-risk stratification.
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RS, LGS and BCB are employees of Signature Genomic Laboratories/PerkinElmer. Nucleoside analogs form the backbone of therapeutic regimes for acute myeloid leukemia (AML) and are used to treat numerous other hematological malignancies, including B-cell acute lymphoblastic leukemia and Hodgkin lymphoma. Chemoresistance presents a major obstacle to the successful treatment of both relapsed and therapy-related AML (t-AML), and altered DNA repair function is one possible mechanism underlying this phenotype. Microsatellite instability, indicative of defective DNA mismatch repair (MMR) is a rare finding in de novo AML but is common in relapsed AML and t-AML, in which it is reported to occur in 30-90% of cases.
1-3 DNA MMR is responsible for maintaining the integrity of the genome by mediating repair of spontaneous DNA damage arising during DNA replication. The MutSa heterodimer (comprising hMSH2 and hMSH6) initiates repair of base/base mispairs. A second complex, MutSb (comprising hMSH2 and hMSH3), mediates repair of shortand long insertion-deletion loops, but has no activity toward mispairs. Subsequent recruitment of the MutLa heterodimer (hMLH1 and hPMS2) facilitates strand excision and gap filling, restoring the DNA to its original structure. Paradoxically, functional DNA MMR facilitates cytotoxicity of certain chemotherapeutic agents, including methylating agents and the base analog 6-thioguanine (6-TG). In both the cases, the mechanisms leading to cell death remain unclear, although one hypothesis suggests that recognition of O 6 -Me G:T or Me 6-TG:T mispairs in DNA by MutSa leads to repeated abortive repair, ultimately resulting in the formation of pro-cytotoxic DNA strand breaks.
1 MMR-defective cells lack the capacity to recognize mispairs and consequently demonstrate a 'tolerant' phenotype and chemoresistance.
The cytotoxicity of Ara-C is mediated in part by incorporation into replicating DNA leading to inhibition of chain extension, stalling of replication forks, activation of the S-phase checkpoint and cell cycle arrest. However, the presence of Ara-C residues at internucleotide linkage positions in leukemic cells treated in vitro provides evidence that Ara-C is not an absolute chain terminator and that extension can occur following incorporation into DNA. 4 Given this, we hypothesized that incorporation of Ara-C might generate a substrate recognized by the MMR machinery and that, as in the case of 6-TG, cellular response to Ara-C-induced toxicity is influenced by MMR status.
MT-1, a B-lymphoblastoid cell line mutated in both copies of MSH6, expressed almost negligible levels of hMSH6 protein compared with its MMR-proficient parental cell line, TK6 (assessed by western immunoblotting). Loss of MSH6 was accompanied by an approximate 50% decrease in hMSH2 protein but no difference in hMSH3 (Figure 1a) . MT-1 was less sensitive to the cytotoxic effects of the methylating agent N-methyl-N-nitrosourea (MNU) (Figure 1b) and to 6-TG ( Figure 1c ) compared with parental TK6 cells, consistent with
